Setting a research agenda for progressive multiple sclerosis: The International Collaborative on Progressive MS

Multiple Sclerosis Journal

Volumn 18, Issue 11, 2012, Pages 1534-1540

  Fox, Robert J ^a   Thompson, Alan ^b   Baker, David ^c   Baneke, Peer ^d   Brown, Doug ^e   Browne, Paul ^d   Chandraratna, Dhia ^d   Ciccarelli, Olga ^b   Coetzee, Timothy ^f   Comi, Giancarlo ^g   Feinstein, Anthony ^h   Kapoor, Raj ⁱ   Lee, Karen ^j   Salvetti, Marco ^k   Sharrock, Kersten ^l   Toosy, Ahmed ^b   Zaratin, Paola ^m   Zuidwijk, Kim ⁿ  

^a CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d Multiple Sclerosis International Federation   (United Kingdom)

^e Great Britain and Northern Ireland   (United Kingdom)

^f National MS Society   (United States)

^g SAN RAFFAELE HOSPITAL   (Italy)

^h UNIVERSITY OF TORONTO   (Canada)

ⁱ NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^j ALS Society of Canada   (Canada)

^k SAPIENZA UNIVERSITY OF ROME   (Italy)

^l Fast Forward LLC   (United States)

^m Italian MS Society   (Italy)

ⁿ MS Research Foundation   (Netherlands)

more..

Author keywords

multiple sclerosis; neuroprotection; progressive multiple sclerosis; rehabilitation; research agenda

Indexed keywords

ANIMAL; BIOASSAY; CLINICAL TRIAL (TOPIC); COOPERATION; DISEASE MODEL; EXPERIMENTAL THERAPY; HUMAN; INTERDISCIPLINARY COMMUNICATION; INTERNATIONAL COOPERATION; MEDICAL RESEARCH; METHODOLOGY; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; ORGANIZATION; ORGANIZATION AND MANAGEMENT; TREATMENT OUTCOME;

ANIMALS; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; COOPERATIVE BEHAVIOR; DISEASE MODELS, ANIMAL; ENDPOINT DETERMINATION; HUMANS; INTERDISCIPLINARY COMMUNICATION; INTERNATIONAL COOPERATION; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; ORGANIZATIONAL OBJECTIVES; RESEARCH DESIGN; THERAPIES, INVESTIGATIONAL; TREATMENT OUTCOME;

EID: 84868023178     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458512458169     Document Type: Review

References (44)

1. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology. 1996 ; 46: 907-911 (Pubitemid 26134623)
2. Antel J, Antel S, Caramanos Z, Arnold D, Kuhlmann T. Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity?. Acta Neuropathol (Berl). 2012 ;:
3. Kapoor R, Furby J, Hayton T, et al. Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Neurol. 2010 ; 9: 681-688
4. Kipp M, van der Star B, Vogel D, et al. Experimental in vivo and in vitro models of multiple sclerosis: EAE and beyond. Multiple Sclerosis and Related Disorders. 2012 ; 1: 15-28
5. Pachner AR. Experimental models of multiple sclerosis. Curr Opin Neurol. 2011 ; 24: 291-299
6. Denic A, Johnson AJ, Bieber AJ, Warrington AE, Rodriguez M, Pirko I. The relevance of animal models in multiple sclerosis research. Pathophysiology. 2011 ; 18: 21-29
7. Fitzner D, Simons M. Chronic progressive multiple sclerosis-pathogenesis of neurodegeneration and therapeutic strategies. Curr Neuropharmacol. 2010 ; 8: 305-315
8. Pryce G, O'Neill JK, Croxford JL, et al. Autoimmune tolerance eliminates relapses but fails to halt progression in a model of multiple sclerosis. J Neuroimmunol. 2005 ; 165: 41-52 (Pubitemid 40984622)
9. Linker RA, Lee DH. Models of autoimmune demyelination in the central nervous system: on the way to translational medicine. Exp Transl Stroke Med. 2009 ; 1: 5
10. Hafler DA, Compston A, Sawcer S, et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med. 2007 ; 357: 851-862 (Pubitemid 47347319)
11. Sawcer S, Hellenthal G, Pirinen M, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011 ; 476: 214-219
12. Bush WS, Sawcer SJ, de Jager PL, et al. Evidence for polygenic susceptibility to multiple sclerosis-the shape of things to come. Am J Hum Genet. 2010 ; 86: 621-625
13. Ayyadurai VA, Dewey CF. CytoSolve: A scalable computational method for dynamic integration of multiple molecular pathway models. Cell Mol Bioeng. 2011 ; 4: 28-45
14. Campillos M, Kuhn M, Gavin AC, Jensen LJ, Bork P. Drug target identification using side-effect similarity. Science. 2008 ; 321: 263-266 (Pubitemid 351989100)
15. Keiser MJ, Setola V, Irwin JJ, et al. Predicting new molecular targets for known drugs. Nature. 2009 ; 462: 175-181
16. Dolgin E. Nonprofit disease groups earmark grants for drug repositioning. Nat Med. 2011 1027 ; 17 :
17. Sormani MP, Bonzano L, Roccatagliata L, Cutter GR, Mancardi GL, Bruzzi P. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Ann Neurol. 2009 ; 65: 268-275
18. Barkhof F, Calabresi PA, Miller DH, Reingold SC. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol. 2009 ; 5: 256-266
19. Fox RJ, Cronin T, Lin J, et al. Measuring myelin repair and axonal loss with diffusion tensor imaging. Am J Neuroradiol. 2011 ; 32: 85-91
20. Inglese M, Madelin G, Oesingmann N, et al. Brain tissue sodium concentration in multiple sclerosis: a sodium imaging study at 3 tesla. Brain. 2010 ; 133: 847-857
21. Paling D, Golay X, Wheeler-Kingshott C, Kapoor R, Miller D. Energy failure in multiple sclerosis and its investigation using MR techniques. J Neurol. 2011 ; 258: 2113-2127
22. Owen DR, Piccini P, Matthews PM. Towards molecular imaging of multiple sclerosis. Mult Scler. 2011 ; 17: 262-272
23. Sellebjerg F, Bornsen L, Khademi M, et al. Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology. 2009 ; 73: 2003-2010
24. Rejdak K, Eikelenboom MJ, Petzold A, et al. CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis. Neurology. 2004 ; 63: 1439-1445 (Pubitemid 39426278)
25. Gunnarsson M, Malmestrom C, Axelsson M, et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol. 2011 ; 69: 83-89
26. Riddell C, Zhao Y, Petkau A. An adaptive clinical trial design for a sensitive subgroup examined in the multiple sclerosis context. Mult Scler. 2011 ; 17: S35
27. Chataway J, Nicholas R, Todd S, et al. A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis. Mult Scler. 2011 ; 17: 81-88
28. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology. 1983 ; 33: 1444-1452 (Pubitemid 14237132)
29. Noseworthy JH, Vandervoort MK, Wong CJ, Ebers GC. Interrater variability with the expanded disability status scale (EDSS) and functional systems (FS) in a multiple sclerosis clinical trial. Neurology. 1990 ; 40: 971-975 (Pubitemid 20201827)
30. Rudick R, Antel J, Confavreux C, et al. Recommendations from the National Multiple Sclerosis Society clinical outcomes assessment task force. Ann Neurol. 1997 ; 42: 379-382 (Pubitemid 127744543)
31. Cohen J, Reingold S, Polman C, Wolinsky J. Trials obotIACoC and Sclerosis iM. Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects. Lancet Neurol. 2012 ;:
32. Miller DM, Allen R. Quality of life in multiple sclerosis: determinants, measurement, and use in clinical practice. Current Neurology & Neuroscience Reports. 2010 ; 10: 397-406
33. U.S. Food and Drug Administration. Guidance for industry patient-reported outcome measures: Use in medical product development to support labeling claims. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/default.htm. Silver Spring, MD: Office of Communications, Division of Drug Information, Food and Drug Administration, 2009.
34. Thompson AJ, Toosy AT, Ciccarelli O. Pharmacological management of symptoms in multiple sclerosis: current approaches and future directions. Lancet Neurol. 2010 ; 9: 1182-1199
35. Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet. 2003 ; 362: 1517-1526 (Pubitemid 37410189)
36. Goodman AD, Brown TR, Krupp LB, et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet. 2009 ; 373: 732-738
37. Ehde DM, Kraft GH, Chwastiak L, et al. Efficacy of paroxetine in treating major depressive disorder in persons with multiple sclerosis. Gen Hosp Psychiatry. 2008 ; 30: 40-48 (Pubitemid 350299496)
38. Mohr DC, Boudewyn AC, Goodkin DE, Bostrom A, Epstein L. Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis. J Consult Clin Psychol. 2001 ; 69: 942-949 (Pubitemid 33140495)
39. Korostil M, Feinstein A. Anxiety disorders and their clinical correlates in multiple sclerosis patients. Mult Scler. 2007 ; 13: 67-72 (Pubitemid 46152763)
40. Pantano P, Mainero C, Caramia F. Functional brain reorganization in multiple sclerosis: evidence from fMRI studies. J Neuroimaging. 2006 ; 16: 104-114
41. Rocca MA, Colombo B, Falini A, et al. Cortical adaptation in patients with MS: a cross-sectional functional MRI study of disease phenotypes. Lancet Neurol. 2005 ; 4: 618-26 (Pubitemid 41317296)
42. Morgen K, Kadom N, Sawaki L, et al. Training-dependent plasticity in patients with multiple sclerosis. Brain. 2004 ; 127: 2506-2517 (Pubitemid 39472979)
43. Penner I, Opwis K, Kappos L. Relation between functional brain imaging, cognitive impairment and cognitive rehabilitation in patients with multiple sclerosis. J Neurol. 2007 ; 254 2: 1153-1157
44. Kim SP, Simeral JD, Hochberg LR, Donoghue JP, Friehs GM, Black MJ. Point-and-click cursor control with an intracortical neural interface system by humans with tetraplegia. IEEE Trans Neural Syst Rehabil Eng. 2011 ; 19: 193-203